Quinazolines are anticancer agents that are clinically used for the targeted treatment of tumors where the ErbB receptors are overexpressed or bear specific mutations. These agents can also act as radiosensitizers. The purpose of this Ph.D. project is the evaluation of new anticancer quinazolines derivatives as radiosensitizers. These will belong to the following categories:
For the purpose of this study, the new produced quinazolines derivatives are evaluated for their anti-cancer activity and for their ability of radiosensitizing. The most promising radiosensitizers of this study will be compared with the current quinazolines that are used nowadays in clinical routine. The ultimate goal is to propose new promising anticancer agents that can also act as radiosensitizers.